Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice

Journal of Experimental Therapeutics and Oncology

Volumn 7, Issue 4, 2008, Pages 291-298

  Ajith, Thekkoottuparambil Ananthanarayanan ^a   Anu, Vijayan ^a   Riji, Thomas ^a  

^a AMALA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antitumor; Atorvastatin; Chemoprevention; Cytotoxicity; Proapoptotic

Indexed keywords

ATORVASTATIN; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRYPAN BLUE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRUCTURE; CONTROLLED STUDY; DALTON LYMPHOMA ASCITES TUMOR; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG EFFICACY; GIEMSA STAIN; IN VITRO STUDY; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR MODEL;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; MALE; MICE; MODELS, CHEMICAL; NEOPLASMS, EXPERIMENTAL; PYRROLES; REACTIVE OXYGEN SPECIES;

EID: 58649113185     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-308, 1981.
2. Sonnenschein E, Glickman L, Goldschmidt M, Mckee L. Body conformation diet and risk of breast cancer in pet dogs: a case-control study. Am J Epidemiol 133: 694-698, 1991.
3. Marnett LJ, Tuttle MA. Comparison of the mutagenecity of MDA and the side products formed during its chemical synthesis. Cancer Res 40: 276-279, 1980.
4. Hristozov D, Gadjeva V, Vlaykova T, Dimitrov G. Evaluation of oxidative stress in patients with cancer. Arch Physiol Biochem 109: 331-336, 2001..
5. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Tr 59: 163-170, 2000.
6. Bartsch H, Nair J. Potential role of lipid peroxidation-derived DNA damage in human colon carcinogenesis: studies on exocyclic base adducts as stable oxidative stress marker. Cancer Detect Prev 26: 4737-4740, 2002.
7. Goluszko P, Nowicki B. Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect Immun 73: 7791-7796, 2005..
8. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320: 165-169, 2004.
9. Guyton KZ, Kesler TW. Oxidative mechanism in carcinogesis. Br Med Bull 49: 523-526,1993.
10. Blauw GJ, Lagaay AM, Westendorp RG. Statins for prevention of stroke. Lancet 352: 144,1998.
11. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82: 3J-10J, 1998.
12. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
13. Fritz G. HMG-Co A reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005.
14. Jiang JD, Wang Y, Roboz J, Strauchen J, Holland, JF, Bekesi JG. Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamine benzoylurea, a new cancericidal compound. Cancer Res 58: 2126-2135, 1998.
15. Yilmaz S, Atessahin A, Sahan E, Karagan I, Ozer S. Protective role of lycopine on adriamicin-induced cardio-toxicity and nephrotoxicity. Toxicology 218: 164-171, 2006.
16. Costantini P, Jocotot E, Decandin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92: 1042-1053, 2000.
17. Reed JC. Apoptosis regulatory proteins as targets for drug discovery. Trends Mol Med 7: 314-318, 2001.
18. Benchekroan MN, Pourquier P, Schott B, Robert J. Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 211: 141-146, 1993.
19. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia (Baltimore) 15: 1398-1407, 2001.
20. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468, 1994.
21. Marcelli, M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer. Cell line LNCaP. Cancer Res 58: 76-83, 1998.
22. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26: 883-891, 2005.
23. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (London) 22: 1139-1148, 2001.
24. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis (London) 22: 1061-1067, 2001.
25. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 90: 317-321, 2003.
26. Ajith TA, Soja M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biol Toxicol 22: 269-274, 2006.
27. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12: 749-756, 2003.